Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(®) to Suppress Enzalutamide-resistant Prostate Cancer Progression

BACKGROUND: While androgen-deprivation-therapy with the recently developed anti-androgen enzalutamide (Enz) shows promising therapeutic benefits in men with metastatic castration-resistant prostate cancer (PCa), many patients develop resistance to Enz, which may involve the induction of the androgen...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur Urol
Autori principali: Wang, Ronghao, Sun, Yin, Li, Lei, Niu, Yuanjie, Lin, Wanying, Lin, Changyi, Antonarakis, Emmanuel S., Luo, Jun, Yeh, Shuyuan, Chang, Chawnshang
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5802348/
https://ncbi.nlm.nih.gov/pubmed/28528814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2017.04.005
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi